Alto differentiates itself through its biomarker-driven approach to psychiatric diseases, moving beyond traditional one-size-fits-all treatments. With multiple candidates in clinical development and recent completion of Phase 2 proof-of-concept enrollment, the company is positioned at the forefront of personalized neuropsychiatry treatment innovation.
Cyborg Score Rationale
As a clinical-stage biotech with innovative technology and recent trial progress, Alto shows promise but carries inherent clinical and regulatory risks. The company has attracted quality institutional investors and demonstrated advancement in its pipeline.
Top Insights
Completed enrollment in Phase 2 proof-of-concept study of ALTO-101 for cognitive impairment in schizophrenia (Feb 2026)
Proprietary Precision Psychiatry Platform uses neurobiology-based biomarkers to predict treatment response, differentiating from competitors
Pipeline includes ALTO-100 in Phase 2b for bipolar depression and ALTO-207 with newly issued method-of-treatment patent
Significant institutional backing with Perceptive Advisors holding 9.99% stake as of November 2025
Named Competitors
Ketamine-based depression treatments — FDA-approved esketamine therapy for treatment-resistant depression
Atypical antipsychotics — Traditional psychiatric medications for schizophrenia and bipolar disorder
Psychedelic-based treatments — Psilocybin and psychedelic therapies for psychiatric conditions